novavax
present
influenza
rsv
candidate
vaccine
data
world
vaccine
congress
washington
gaithersburg
globe
newswire
novavax
nasdaq
nvax
late
stage
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
present
lead
vaccine
candidates
company
influenza
respiratory
syncytial
virus
rsv
vaccines
presentations
part
world
vaccine
congress
washington
taking
place
virtually
september
gregory
glenn
president
research
development
vivek
shinde
vice
president
clinical
development
join
global
public
health
epidemiology
regulatory
industry
leaders
share
expertise
latest
research
related
virus
vaccine
development
address
global
health
september
presentation
title
recombinant
nanoparticle
vaccine
platform
technology
eid
emerging
infectious
diseases
time
et
presenter
gregory
glenn
october
presentation
title
phase
beyond
maternal
rsv
older
adult
influenza
vaccine
program
time
et
presenter
gregory
glenn
presentation
title
new
phase
nanoflu
data
features
new
immunity
data
time
pm
et
presenter
vivek
shinde
information
congress
register
please
click
vaccine
candidate
engineered
genetic
sequence
virus
causes
disease
created
using
novavax
recombinant
nanoparticle
technology
generate
antigen
derived
coronavirus
spike
protein
contains
novavax
patented
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
contains
purified
protein
antigens
replicate
cause
preclinical
trials
demonstrated
indication
antibodies
block
binding
spike
protein
receptors
targeted
virus
critical
aspect
effective
vaccine
protection
phase
portion
phase
clinical
trial
generally
elicited
robust
antibody
responses
numerically
superior
seen
human
convalescent
sera
also
evaluated
phase
trial
uk
two
ongoing
phase
studies
began
august
phase
trial
south
africa
phase
continuation
australia
novavax
secured
billion
funding
global
coronavirus
vaccine
program
including
million
funding
coalition
epidemic
preparedness
innovations
cepi
resvax
resvax
rsv
fusion
f
protein
recombinant
nanoparticle
vaccine
aluminum
phosphate
adjuvant
developed
protect
infants
rsv
disease
via
maternal
immunization
may
offer
best
method
protection
rsv
disease
infants
first
months
life
resvax
evaluated
global
phase
clinical
trial
pregnant
women
least
received
vaccine
infants
prepare
supported
million
grant
bill
melinda
gates
foundation
bmgf
nanoflu
recombinant
hemagglutinin
ha
protein
nanoparticle
influenza
vaccine
produced
novavax
insect
cell
baculovirus
system
nanoflu
uses
ha
amino
acid
protein
sequences
recommended
circulating
virus
ha
sequences
nanoflu
contains
novavax
patented
matrixm
adjuvant
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
undergoing
clinical
trials
vaccine
candidate
virus
causes
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
vaccine
candidates
incorporate
novavax
proprietary
adjuvant
order
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
information
visit
connect
us
twitter
linkedin
investors
silvia
taylor
erika
trahan
ir
